| Auvelity (bupropion/dextromethorphan) / Axsome Therap |
NCT06223880: A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms |
|
|
| Recruiting | 4 | 350 | US | AXS-05, Bupropion | Axsome Therapeutics, Inc. | Major Depressive Disorder | 03/26 | 03/26 | | |
AXS-05-AD-303, NCT04947553: A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation |
|
|
| Enrolling by invitation | 3 | 300 | Canada, US | AXS-05 (dextromethorphan-bupropion), Placebo | Axsome Therapeutics, Inc. | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 12/24 | 12/24 | | |
ADVANCE-2, NCT05557409: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation |
|
|
| Recruiting | 3 | 350 | US | AXS-05, Placebo | Axsome Therapeutics, Inc. | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation | 06/25 | 06/25 | | |
| Not yet recruiting | 2 | 60 | US | AXS-05, Bupropion/dextromethorphan, Bupropion SR, Wellbutrin SR, Zyban SR | James Davis, Axsome Therapeutics, Inc. | Smoking Cessation, Smoking, Cigarette, Nicotine Dependence | 12/18 | 01/19 | | |
TARGET, NCT04971291: An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients |
|
|
| Enrolling by invitation | 2 | 312 | US | AXS-05, Bupropion SR | Axsome Therapeutics, Inc. | Major Depressive Disorder, Treatment Resistant Depression | 07/21 | 07/21 | | |
NCT05976646: Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion |
|
|
| Recruiting | 1/2 | 18 | US | Placebo, Auvelity | Virginia Commonwealth University, National Institute on Drug Abuse (NIDA) | Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder | 01/25 | 01/25 | | |
